



DT16 PCT/PTO JUN 11 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

LIANG ET AL.

Serial No: 10/070560

Filed: March 8, 2002

For: METHOD OF PRODUCING AND PURIFYING)  
ENDOSTATIN PROTEIN

Group Art No: Unassigned

Examiner: Unassigned

**INFORMATION DISCLOSURE STATEMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

The citation of information on the attached Form PTO/SB/08A, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of all listed items is enclosed. The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

By: Theodore M. Green  
Reg. No. 41,801

KILPATRICK STOCKTON LLP  
Suite 2800  
1100 Peachtree Road  
Atlanta, Georgia 30309  
(404) 815-6500  
Our Docket: 05213-0551US (43170-258385)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC, 20231, on June 6, 2002.

By:

Theodore M. Green - Reg. No. 41,801

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Complete if Known

Application No.	10/070560
Filing Date	11/30/2001
First Named Inventor	Liang et al.
Group Art Unit	Not Yet Assigned
Examiner Name	Unassigned
Attorney Docket Number	05213-0551US(43170-258385)

Sheet 1 of 3

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)			
/SHS/	1	5,854,205		O'Reilly et al.	12/29/1998	

Examiner  
Signature

Shulamith H. Shafer

Digitally signed by Shulamith H. Shafer  
DN: cn=Shulamith H. Shafer, o=USPTO, ou=USPTO,  
email=shs@uspto.gov, c=US  
Date: 2007.11.13 17:36:51 -0500Date  
Considered

11/12/2007

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

## Complete Information

Application No.	10/070560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	05213-0551US(43170-258385)

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Kind Code <sup>3</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Office <sup>2</sup>	Number <sup>4</sup>					
/SHS/	2	WO	96/08274	A2	Prizm Pharmaceuticals, Inc.	03/21/1996		
/SHS/	3	WO	99/26480	A1	Genetix Pharmaceuticals, Inc. and MIT	06/03/1999		

Examiner  
Signature

Shulamith H. Shafer

Digitally signed by Shulamith H. Shafer  
DN: cn=Shulamith H. Shafer, o=USPTO, ou=USPTO,  
email=shs@uspto.gov  
Date: 2002.11.12 17:28:49 -0500
Date  
Considered

11/12/2007

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Substitute for Form 1449/A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## Complete if Known

Application No.	10/070560
Filing Date	03/08/2002
First Named Inventor	Liang et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	05213-0551US(43170-258385)

Sheet	3	of	3
-------	---	----	---

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/SHS	4	<b>Author:</b> BOEHM ET AL. <b>Title:</b> Disruption of the KEX1 Gene in <i>Pichia pastoris</i> Allows Expression of Full-Length Murine and Human Endostatin <b>Publ:</b> <b>Yeast</b> <b>Vol/Iss:</b> 15 <b>Pages:</b> 563-572 <b>Date:</b> 1999	
	5	<b>Author:</b> BOEHM ET AL. <b>Title:</b> Zinc-Binding of Endostatin is Essential for Its Antiangiogenic Activity <b>Publ:</b> <b>Biochemical and Biophysical Research Communications</b> <b>Vol/Iss:</b> 252 <b>Pages:</b> 190-194 <b>Date:</b> 1998	
	6	<b>Author:</b> DHANABAL ET AL. <b>Title:</b> Endostatin: Yeast Production, Mutants, and Antitumor Effect in Renal Cell Carcinoma <b>Publ:</b> <b>Cancer Research</b> <b>Vol/Iss:</b> 59 <b>Pages:</b> 189-197 <b>Date:</b> 01/01/1999	
	7	<b>Author:</b> JOHN ET AL. <b>Title:</b> Novel Glycosylated Forms of Human Plasma Endostatin and Circulating Endostatin-Related Fragments of Collagen XV <b>Publ:</b> <b>Biochemistry</b> <b>Vol/Iss:</b> 38 (32) <b>Pages:</b> 10217-10224 <b>Date:</b> 08/10/1999	
	8	<b>Author:</b> SHEPARD ET AL. <b>Title:</b> Purification of Recombinant Human Endostatin and Angiostatin from <i>Pichia Pastoris</i> Fermentation Broth: Expanded Bed Adsorption Chromatography Method Development and Scale Up <b>Publ:</b> <b>Abstracts of Papers American Chemical Society</b> <b>Vol/Iss:</b> 219 (1-2) <b>Pages:</b> BIOT 212 <b>Date:</b> 03/26/2000	
	9	<b>Author:</b> STANDKER et al. <b>Title:</b> Isolation and characterization of the circulating form of human endostatin <b>Publ:</b> <b>FEBS Letters</b> <b>Vol/Iss:</b> 420 <b>Pages:</b> 129-133 <b>Date:</b> 1997	

Examiner  
Signature

Shulamith H. Shafer

 Digitally signed by Shulamith H. Shafer  
 DN: cn=Shulamith H. Shafer, o=USPTO, ou=USPTO, email=shulamith.h.shafer@uspto.gov, c=US
 
Date  
Considered

11/05/2007

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.